The American healthcare system has an uncanny talent for finding the softest targets. The latest: preschoolers with autism diagnoses, whose treatment has become a multibillion-dollar extraction scheme dressed up as compassionate care.
A detailed investigation has exposed how a network of autism therapy clinics—many backed by private equity—have systematically exploited Medicaid's reimbursement structure, billing for maximum allowable hours regardless of clinical necessity. The playbook is elegant in its cynicism: acquire clinics in states with generous Medicaid autism benefits, push therapists to hit billing quotas, and discharge patients who become unprofitable.
The numbers game
Applied Behavior Analysis, or ABA, is the gold-standard treatment for autism spectrum disorder. Medicaid typically covers 25 to 40 hours weekly for qualifying children. The problem isn't the therapy—it's who's deciding how much each child receives. Clinics have financial incentives to prescribe maximum hours, and the assessments determining treatment intensity are conducted by the same organizations that profit from higher prescriptions.
The result is predictable. Children who might benefit from ten hours weekly are routinely prescribed thirty. Therapists report pressure to maintain caseloads regardless of patient progress. When families push back or children age out of the most lucrative reimbursement brackets, they're quietly shown the door.
Private equity's healthcare playbook
The autism therapy sector has attracted significant private equity investment over the past decade, with firms recognizing the combination of fragmented markets, recurring revenue, and government-backed payment streams. The consolidation wave has created regional chains with sophisticated billing operations and, critics argue, misaligned incentives.
State Medicaid programs, already stretched thin, lack the resources for meaningful oversight. Audits are rare; when they occur, clinics have learned to document just enough to survive scrutiny. The children at the center of this system—nonverbal three-year-olds, overwhelmed parents desperate for help—are poorly positioned to advocate for themselves.
Our take
This is what happens when you combine a genuine public health need, an opaque reimbursement system, and investors hunting yield. The autism therapy industry isn't uniquely predatory—it's following the template established by dialysis chains, nursing homes, and emergency staffing firms before it. The solution isn't complicated: independent treatment assessments, meaningful audit capacity, and clawback provisions with teeth. Whether any state has the political will to implement them against a well-funded lobbying operation is another question entirely.
